Wisdomi
↗Clarkdale, Arizona, USA
Wisdomi is an AI-driven biotechnology company focused on precision medicine and drug discovery, primarily in the field of oncology. The company leverages its proprietary 'Soleri' platform to integrate multi-omics data with advanced artificial intelligence to optimize therapeutic development and patient stratification.
Wisdomi is part of a broader ecosystem located at the Grand Canyon Foundation Compound of Science & Art in Arizona. This initiative follows the arcology principles of architect Paolo Soleri, aiming to create a self-sustaining community that integrates cutting-edge scientific research, biotechnology, and sustainable living.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Early Stage / Stealth
Total Raised:$250M (Targeted for the broader Soleri Compound project)
Investors:Private Investors, Government Grants, Grand Canyon Foundation
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Small molecule, Precision Medicine, AI-driven Discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Grand Canyon Foundation (Affiliate)
Key Partnerships:Zymeworks (Board connection), Puma Biotechnology (Board connection), Summit Therapeutics (Board connection)
COMPETITION
Position:Emerging
Competitors:Recursion Pharmaceuticals, Exscientia, Insilico Medicine, Schrödinger
LEADERSHIP
Key Executives:
Alessandra Cesano - President and CMO
Scientific Founders:Alessandra Cesano
Board Members:Alessandra Cesano
LINKS
Website:wsoleri.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Wisdomi. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.